Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice

Авторы: Tjulandin Sergey, Demidov Lev, Moiseyenko Vladimir, Protsenko Svetlana, Semiglazova Tatiana, Odintsova Svetlana, Zukov Ruslan, Lazarev Sergey, Makarova Yuliya, Nechaeva Marina, Sakaeva Dina, Andreev Aleksey, Tarasova Anna, Fadeyeva Natalya, Shustova Mariia, Kuryshev Ivan
Журнал: European Journal of Cancer
Том: 149
Год издания: 2021
Издательство: Pergamon Press Ltd.
Местоположение издательства: United Kingdom
Первая страница: 222
Последняя страница: 232
DOI: 10.1016/j.ejca.2021.02.030
Аннотация: Prolgolimab is an IgG1 anti-PD-1 (programmed cell death protein 1) monoclonal antibody containing the Fc-silencing 'LALA' mutation. We assessed the efficacy and safety of two dosing regimens of prolgolimab in patients with advanced melanoma in a multicenter open-label parallel-arm phase II trial (MIRACULUM). We present the final analysis after 1 year of follow-up and additional efficacy results from 2 years of follow-up.
Добавил в систему: Демидов Лев Вадимович

	ИСТИНА	Войти в систему Регистрация
	ИСТИНА ИНХС РАН
	Главная Поиск Статистика О проекте Помощь

ИСТИНА